Kilter Group LLC Takes Position in Amgen Inc. (NASDAQ:AMGN)

Kilter Group LLC bought a new position in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 1,282 shares of the medical research company's stock, valued at approximately $334,000.

A number of other large investors have also recently made changes to their positions in AMGN. Capital World Investors increased its stake in shares of Amgen by 1,292.0% during the fourth quarter. Capital World Investors now owns 6,495,710 shares of the medical research company's stock worth $1,693,042,000 after buying an additional 6,029,058 shares during the period. Norges Bank purchased a new stake in shares of Amgen during the fourth quarter worth approximately $1,541,991,000. Capital International Investors increased its stake in shares of Amgen by 40.1% during the fourth quarter. Capital International Investors now owns 12,212,065 shares of the medical research company's stock worth $3,182,843,000 after buying an additional 3,495,503 shares during the period. Charles Schwab Investment Management Inc. increased its stake in shares of Amgen by 25.4% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 13,205,604 shares of the medical research company's stock worth $3,441,909,000 after buying an additional 2,672,975 shares during the period. Finally, Raymond James Financial Inc. purchased a new stake in shares of Amgen during the fourth quarter worth approximately $401,913,000. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Amgen Price Performance

Amgen stock traded up $3.48 during midday trading on Friday, reaching $287.02. 5,437,576 shares of the company were exchanged, compared to its average volume of 2,813,486. The company has a market capitalization of $154.33 billion, a price-to-earnings ratio of 38.02, a P/E/G ratio of 2.63 and a beta of 0.51. The firm's 50-day simple moving average is $283.46 and its 200-day simple moving average is $285.42. Amgen Inc. has a 1 year low of $253.30 and a 1 year high of $346.85. The company has a debt-to-equity ratio of 9.62, a quick ratio of 0.95 and a current ratio of 1.26.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The medical research company reported $4.90 EPS for the quarter, topping analysts' consensus estimates of $4.18 by $0.72. The firm had revenue of $8.15 billion during the quarter, compared to analysts' expectations of $8.05 billion. Amgen had a return on equity of 176.32% and a net margin of 12.24%. The firm's quarterly revenue was up 9.4% compared to the same quarter last year. During the same quarter last year, the business posted $3.96 EPS. On average, analysts anticipate that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Friday, May 16th will be issued a $2.38 dividend. This represents a $9.52 annualized dividend and a yield of 3.32%. The ex-dividend date is Friday, May 16th. Amgen's dividend payout ratio (DPR) is 86.86%.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. Morgan Stanley restated an "equal weight" rating on shares of Amgen in a research note on Friday, May 2nd. Erste Group Bank downgraded Amgen from a "strong-buy" rating to a "hold" rating in a report on Thursday, May 8th. Mizuho increased their price objective on Amgen from $235.00 to $280.00 and gave the company a "neutral" rating in a report on Wednesday, May 7th. Citigroup reissued a "neutral" rating on shares of Amgen in a report on Wednesday, February 5th. Finally, Wall Street Zen raised Amgen from a "buy" rating to a "strong-buy" rating in a report on Sunday, May 18th. Two research analysts have rated the stock with a sell rating, twelve have given a hold rating, nine have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, Amgen presently has a consensus rating of "Hold" and an average price target of $309.22.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.